TY - JOUR
T1 - Deregulated mucosal immune surveillance through gut-Associated regulatory t cells and PD-1 + t cells in human colorectal cancer
AU - Fujimoto, Hanae
AU - Saito, Yoriko
AU - Ohuchida, Kenoki
AU - Kawakami, Eiryo
AU - Fujiki, Saera
AU - Watanabe, Takashi
AU - Ono, Rintaro
AU - Kaneko, Akiko
AU - Takagi, Shinsuke
AU - Najima, Yuho
AU - Hijikata, Atsushi
AU - Cui, Lin
AU - Ueki, Takashi
AU - Oda, Yoshinao
AU - Hori, Shohei
AU - Ohara, Osamu
AU - Nakamura, Masafumi
AU - Saito, Takashi
AU - Ishikawa, Fumihiko
N1 - Funding Information:
This work was supported by grants from the Japan Society for the Promotion of Science.
Publisher Copyright:
Copyright © 2018 by The American Association of Immunologists, Inc.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Disturbed balance between immune surveillance and tolerance May lead to poor clinical outcomes in some malignancies. In paired analyses of adenocarcinoma and normal mucosa from 142 patients, we found a significant increase of the CD4/CD8 ratio and accumulation of regulatory T cells (Tregs) within the adenocarcinoma. The increased frequency of Tregs correlated with the local infiltration and extension of the tumor. There was concurrent maturation arrest, upregulation of programmed death-1 expression, and functional impairment in CD8 + T cells (CTLs) isolated from the adenocarcinoma. Adenocarcinoma-associated Tregs directly inhibit the function of normal human CTLs in vitro. With histopathological analysis, Foxp3 + Tregs were preferentially located in stroma. Concurrent transcriptome analysis of epithelial cells, stromal cells, and T cell subsets obtained from carcinomatous and normal intestinal samples from patients revealed a distinct gene expression signature in colorectal adenocarcinoma–associated Tregs, with overexpression of CCR1, CCR8, and TNFRSF9, whereas their ligands CCL4 and TNFSF9 were found upregulated in cancerous epithelium. Overexpression of WNT2 and CADM1, associated with carcinogenesis and metastasis, in cancer-associated stromal cells suggests that both cancer cells and stromal cells play important roles in the development and progression of colorectal cancer through the formation of a tumor microenvironment. The identification of CTL anergy by Tregs and the unique gene expression signature of human Tregs and stromal cells in colorectal cancer patients May facilitate the development of new therapeutics against malignancies. The Journal of Immunology, 2018, 200: 3291–3303.
AB - Disturbed balance between immune surveillance and tolerance May lead to poor clinical outcomes in some malignancies. In paired analyses of adenocarcinoma and normal mucosa from 142 patients, we found a significant increase of the CD4/CD8 ratio and accumulation of regulatory T cells (Tregs) within the adenocarcinoma. The increased frequency of Tregs correlated with the local infiltration and extension of the tumor. There was concurrent maturation arrest, upregulation of programmed death-1 expression, and functional impairment in CD8 + T cells (CTLs) isolated from the adenocarcinoma. Adenocarcinoma-associated Tregs directly inhibit the function of normal human CTLs in vitro. With histopathological analysis, Foxp3 + Tregs were preferentially located in stroma. Concurrent transcriptome analysis of epithelial cells, stromal cells, and T cell subsets obtained from carcinomatous and normal intestinal samples from patients revealed a distinct gene expression signature in colorectal adenocarcinoma–associated Tregs, with overexpression of CCR1, CCR8, and TNFRSF9, whereas their ligands CCL4 and TNFSF9 were found upregulated in cancerous epithelium. Overexpression of WNT2 and CADM1, associated with carcinogenesis and metastasis, in cancer-associated stromal cells suggests that both cancer cells and stromal cells play important roles in the development and progression of colorectal cancer through the formation of a tumor microenvironment. The identification of CTL anergy by Tregs and the unique gene expression signature of human Tregs and stromal cells in colorectal cancer patients May facilitate the development of new therapeutics against malignancies. The Journal of Immunology, 2018, 200: 3291–3303.
UR - http://www.scopus.com/inward/record.url?scp=85046303544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046303544&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1701222
DO - 10.4049/jimmunol.1701222
M3 - Article
C2 - 29581358
AN - SCOPUS:85046303544
SN - 0022-1767
VL - 200
SP - 3291
EP - 3303
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -